Surface modification of silica core-shell nanocapsules: biomedical implications.

In this article we present the synthesis of oil core silica shell nanocapsules with different shell thicknesses. The surface of the nanocapsules was modified with polyethyleoxide (PEO) and succinic anhydride. Two biomedical tests were then used to study the biocompatibility properties of these nanocapsules with different surface treatments, hemolysis and thromboelastography (TEG).

Pluronic microemulsions as nanoreservoirs for extraction of bupivacaine from normal saline.

We hypothesized that custom-designed microemulsions would effectively scavenge compounds from bulk media. Pluronic-based oil-in-water microemulsions were synthesized that efficiently reduced the free concentration of the local anesthetic bupivacaine in 0.9% NaCl.

Treatment of Local Anesthetic-Induced Cardiotoxicity Using Drug Scavenging Nanoparticles.

Because of its ability to create structures of nanoscale dimension with large aggregate particle surface area-to-volume ratios, nanotechnology offers new opportunities to treat drug poisonings. Emulsion-based nanoparticles (diameter: 118.4 nm) extracted bupivacaine from the aqueous phase in a physiological salt solution and attenuated the drug's cardiotoxicity in guinea pig heart to a greater extent than did a macroemulsion (432.

Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses.

Intranasal (i.n.) administration of an Escherichia coli-expressed chimeric VP6 protein from the EDIM strain of murine rotavirus to adult BALB/c (H-2(d)) mice along with LT(R192G), an attenuated mutant of the mucosal adjuvant E.

The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.

Intranasal (i.n.) immunization of BALB/c mice with chimeric murine rotavirus EDIM (epizootic diarrhea of infant mice) VP6 and attenuated E.

CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G).

Intranasal immunization of mice with a chimeric VP6 protein and the mucosal adjuvant Escherichia coli heat labile toxin LT(R192G) induces nearly complete protection against murine rotavirus (strain EDIM [epizootic diarrhea of infant mice virus]) shedding for at least 1 year. The aim of this study was to identify the protective lymphocytes elicited by this new vaccine candidate. Immunization of mouse strains lacking one or more lymphocyte populations revealed that protection was dependent on alphabeta T cells but mice lacking gammadelta T cells and B cells remained fully protected.